|
Patent landscape, scope, and claims: |
US Patent 11,478,471 Scope, Claims, and US Patent Landscape for 2S,4R Ketoconazole Enantiomer Therapies for Elevated Cortisol
US Drug Patent 11,478,471 claims a narrow, enantiomer-enriched ketoconazole treatment method in patients with disease or conditions associated with elevated cortisol levels, where the ketoconazole component is enriched in the 2S,4R enantiomer at defined thresholds (≥90% (claim 1), ≥95% (claim 2), ≥99% (claim 3)). The claim set is method-of-treatment focused, with the core novelty and infringement trigger being stereochemical composition specifications, not a particular formulation vehicle, dose regimen, disease name, or administration route.
Bottom line for freedom-to-operate (FTO): risk centers on any US commercialization of an enantiomerically enriched 2S,4R ketoconazole product (or label-supported method) targeting elevated cortisol indications, where the ketoconazole fraction meets the claimed enrichment thresholds. Existing US “ketoconazole for Cushing’s syndrome/hypercortisolism” IP may cover disease-method use broadly, but 11,478,471 pushes enforcement toward manufactured enantiomer purity.
What does US Patent 11,478,471 claim about 2S,4R ketoconazole for elevated cortisol?
Core claim theme (independent concept): a method of treating a cortisol-elevated condition by administering a composition containing a ketoconazole component that is predominantly the 2S,4R enantiomer.
Claim-by-claim scope
Claim 1 (≥90% 2S,4R):
- Treat a “disease or condition associated with elevated cortisol levels”
- Administer a composition with a ketoconazole component
- In the composition, at least 90% of the ketoconazole component is 2S,4R
Claim 2 (≥95% 2S,4R):
- Same treatment framing
- Threshold increases to at least 95%
Claim 3 (≥99% 2S,4R):
- Same treatment framing
- Threshold increases to at least 99%
What is not claimed (important boundaries)
- No specific route of administration is recited (oral, IV, depot, etc. are not limited on the face of the claims).
- No dosage form is recited (tablet, capsule, suspension, etc. not specified).
- No specific dosing regimen (mg, frequency, titration) is recited.
- No specific disease name (e.g., Cushing’s syndrome) is recited; instead the claims use a functional disease category tied to elevated cortisol.
- The claims do not expressly require a specific formulation composition beyond a “composition comprising a ketoconazole component.”
- The claims do not tie to a particular manufacturing method (e.g., chiral resolution, asymmetric synthesis, purification).
Infringement posture implied by the claim language
- Direct infringement is triggered by the combination of:
- treatment of a cortisol-elevated condition, and
- administration of a composition containing ketoconazole where the ketoconazole stereochemistry meets enrichment thresholds.
- Evidence will typically focus on:
- patient indication (labeling, medical records, and physician instructions),
- drug product specification (enantiomeric composition), and
- analytical confirmation (chiral HPLC/GC methods or equivalent).
How do the “≥90% / ≥95% / ≥99%” enantiomer limits change the infringement risk profile?
The claims create a tiered purity ladder. Each higher claim level requires higher enrichment, so infringement analysis should treat each threshold as an independent line.
Risk mapping for commercial products
- A product with ~92% 2S,4R can still implicate claim 1 but may avoid claims 2 and 3 if it is below 95%.
- A product at ~96% can implicate claims 1 and 2.
- A product at ~99.2% can implicate claims 1, 2, and 3.
Manufacturing variability and spec strategy
Even if the mean lot purity is high, litigation frequently tests:
- lot-to-lot variation,
- stability-driven conversion or racemization risk (if any),
- analytical method suitability and validation (accuracy at the claimed threshold, detection limits, bias).
Products near the boundary (e.g., 94–96%) carry the highest litigation uncertainty because a small analytical shift can move a lot across the 95% or 99% lines.
What diseases or conditions with elevated cortisol are likely within the claim category?
The claims cover “a disease or condition associated with elevated cortisol levels.” This category is broader than any single labeled indication and can include:
- Cushing’s syndrome / hypercortisolism due to endogenous causes
- Adrenocortical hyperfunction states with elevated cortisol
- Other hypercortisolemic syndromes where cortisol excess is the defining physiological marker
Legal impact: courts often construe “associated with elevated cortisol levels” using ordinary meaning and evidence of cortisol elevation in the patient population. Because the claims do not name specific diseases, the treatment context becomes central.
What formulations are protected by US 11,478,471 if the claims focus on enantiomer purity?
The claims cover a “composition comprising a ketoconazole component” with a defined enantiomer enrichment. That structure typically captures:
- Any dosage form containing ketoconazole meeting the 2S,4R enrichment thresholds
- Any excipients or formulation components, because excipients are not limited in the claims
Key limitation: no chiral carrier or excipient requirement
If the protected element is solely ketoconazole enantiomer composition, then:
- changing excipients or dosage form likely does not avoid infringement if the ketoconazole enantiomer purity remains within the claimed range.
- a non-infringing design would usually reduce 2S,4R fraction below the threshold or avoid the claimed treatment context.
Is US 11,478,471 a composition patent, a method patent, or both?
It is a method for treating claim set. The claims are infringement-relevant when a healthcare provider (or another actor) administers the composition as part of treatment.
Why that matters
- A “composition-only” product may not be actionable unless tied to a “method for treating” elevated cortisol conditions (directly or through induced-conduct theories).
- Orange Book listing status depends on whether the patent is listed in connection with an FDA-approved drug product and on its statutory basis. The claim text you provided is method-of-treatment, but without FDA listing data the Orange Book status cannot be established here.
What patent landscape exists around stereoselective ketoconazole for steroidogenesis and cortisol suppression in the US?
Landscape clusters relevant to 11,478,471
- Ketoconazole use for hypercortisolism / Cushing’s syndrome
- Broad method-of-use IP may cover ketoconazole’s therapeutic use in suppressing cortisol.
- Stereochemistry or enantiomer-specific ketoconazole purity
- Enantiomer enrichment patents focus on manufacturing purity, resolution, or stabilized enantiomer fractions.
- Formulation patents for ketoconazole
- Solubility, dissolution, bioavailability, and dosage form IP can coexist, though 11,478,471 likely does not depend on those details.
- Process patents for chiral enrichment
- Even though 11,478,471 is a method-of-treatment claim, other patents can control the supply chain by constraining how 2S,4R enrichment is manufactured.
How 11,478,471 likely fits
- If there are prior patents on ketoconazole therapy for elevated cortisol, 11,478,471 is positioned as a refinement that narrows the claim to 2S,4R-enriched ketoconazole.
- If there are prior patents on enantiomer enrichment, 11,478,471 adds a clinical method enforcement lever for products where the drug is administered for hypercortisol conditions.
When does US 11,478,471 lose exclusivity in the US?
You provided only the claim text and patent number. No filing date, priority date, or patent term adjustment data is included here. Without those dates, an exclusivity or expiration timeline cannot be computed.
What generic entry risks exist for 2S,4R ketoconazole under a Paragraph IV theory?
A Paragraph IV certification would hinge on:
- the relevance of 11,478,471 to the generic product, and
- whether the generic product:
- meets the claimed 2S,4R enrichment threshold, and
- is used/marketed under an elevated cortisol method consistent with infringement.
Typical generic risk profile
- If the generic uses racemic ketoconazole or an enantiomer mixture below 90% 2S,4R, it can avoid the literal claim thresholds.
- If the generic uses enantiomerically enriched ketoconazole and the product is marketed for elevated cortisol conditions, infringement risk rises quickly.
- If the generic design reduces to ≤89.9%, it can fall outside claim 1, but that still leaves possible exposure to other patents in the estate.
How strong is the patent estate for 2S,4R-enriched ketoconazole therapies?
Strength analysis requires the patent family, prosecution history, claim construction posture, and the set of co-pending/related US patents. Those are not provided. Based strictly on claim structure:
- The claims are clear, objective thresholds (90/95/99%).
- The claims are narrow in concept (enantiomer fraction + elevated cortisol treatment).
- The claims omit disease specificity and formulation limits, which can broaden the method-of-treatment reach within the elevated cortisol category.
Without the estate mapping, litigation outcomes, or a list of related US applications, a quantified strength score is not supportable here.
What patent litigation could affect enforcement of US 11,478,471?
Litigation posture depends on:
- whether the patent is asserted in district court,
- whether there are prior IPRs or PTAB challenges,
- and whether any settlements narrow claim interpretation.
No litigation docket, PTAB history, or enforcement actions are provided, so a specific litigation impact cannot be stated.
How does 11,478,471 compare with broader ketoconazole patents for Cushing’s syndrome?
Comparison axis: specificity
- Broader ketoconazole method patents typically claim “treating Cushing’s syndrome/hypercortisolism” using ketoconazole, without chiral constraints.
- 11,478,471 adds the chiral purity constraint: the method is only claimed when the ketoconazole component is ≥90/95/99% 2S,4R.
Practical implication for compendial or label-based prescribing
Even if ketoconazole is broadly indicated for steroidogenesis disorders, 11,478,471 creates enforcement leverage against products that supply enriched 2S,4R ketoconazole for those same indications.
Key Takeaways
- US 11,478,471 is a method-of-treatment patent for elevated cortisol conditions using a composition containing ketoconazole enriched in the 2S,4R enantiomer.
- Claim infringement hinges on objective purity thresholds:
- claim 1: ≥90% 2S,4R
- claim 2: ≥95% 2S,4R
- claim 3: ≥99% 2S,4R
- The claims do not restrict dosage form, route, excipients, or disease name, increasing the chance that any administration for a cortisol-elevated condition can fall within scope if the enantiomer purity threshold is met.
- Generic and licensing risk concentrates on whether a competitor’s ketoconazole product is manufactured and specified to remain within or outside the 90/95/99% enantiomer enrichment bands.
FAQs
1) What analytical methods matter most to prove whether a ketoconazole lot meets the 2S,4R thresholds in US 11,478,471?
Chiral chromatography methods (e.g., chiral HPLC) with validated quantitation around the threshold percentages are typically central because the claims require specific enantiomer fractions.
2) Does US 11,478,471 require the patient to have Cushing’s syndrome specifically?
No. The claim language is framed as “a disease or condition associated with elevated cortisol levels,” which is broader than a single named diagnosis.
3) Can a product avoid infringement of claim 1 by using ketoconazole with 89% 2S,4R?
On the claim language alone, reducing the 2S,4R fraction below 90% is a direct path to non-literal coverage for claim 1, assuming no other related claims apply.
4) If a generic product contains ≥95% 2S,4R ketoconazole, is infringement automatic?
Not necessarily. The method is for treating elevated cortisol conditions, so infringement also depends on the treatment context, including how the product is administered and used.
5) Do formulation changes (tablet vs capsule) affect infringement of US 11,478,471?
The claims focus on the ketoconazole enantiomer enrichment and the treatment method; excipient or dosage form changes do not avoid infringement if the administered ketoconazole component meets the same 2S,4R threshold.
References (APA)
- US Patent 11,478,471 claim text provided in prompt.
More… ↓
⤷ Start Trial
|
